Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

BraIN A Conceptually New 3-Dimensional Blood-Brain Barrier Model- Designed to Overcome the Limited Predictive Power of Current In Vitro Systems

Coordinator
Universitaet Muenster, Germany
Runs
1 October 2026 to 31 March 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101332595

What the project is doing

In the project's own words, from its summary on CORDIS.

Therapeutic access to the brain is severely restricted by the blood–brain barrier (BBB), and current in vitro models fail to reliably predict drug penetration mainly because they fail to recapitulate key aspects of BBB physiology. Existing 2D and 3D models oversimplify multicellular architecture, neglect the astroglial barrier, and lack physiologically relevant mechanical and biochemical environments, contributing to high failure rates in CNS drug development.

This significantly hampers the development of better treatments for neurological disorders, which affect over 3.4 billion people worldwide. We propose BraIN, a conceptually new, human 3D BBB model that embeds iPSC-derived brain-like endothelial cells, pericytes, and a functional astroglial barrier within a tuneable vinyl sulfone dextran (DexVS) hydrogel. Unlike other hydrogels, DexVS enables independent control of stiffness, adhesiveness, and degradability, supporting formation of a tight endothelial barrier, basement membrane deposition, and polarized astrocyte endfeet formation.

By translating our in vivo knowledge of the BBB to an in vitro engineered system, BraIN overcomes limitations of existing models and provides a scalable, reproducible model for predictive CNS drug screening and mechanistic studies of astroglial barrier biology. This Proof-of-Concept project will optimize, validate, and scale the BraIN spheroid system, leading to in the future to a robust, patentable model for early-stage pharmaceutical and biotechnology applications.

Success will enable reliable assessment of BBB penetration, reduce late-stage drug development failures, and create a foundation for licensing, collaborative development, or spin-out formation.

Topics

Who is involved

OrganisationCityCountryRole
Universitaet MuensterMuensterGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI